Rebecca Vaught started her biotech company just ahead of COVID-19, but she shares on the Houston Innovators Podcast that it's meant more opportunities than challenges. Photo courtesy of Van Heron Labs

While startups everywhere are struggling to adapt in the tumultuous times of COVID-19, Rebecca Vaught and her company, having launched just ahead of the pandemic, don't actually know any other way of existing.

After watching some of her friends thrive in Houston's life science ecosystem, she knew Houston was the place she wanted to start the company that she'd been envisioning and plotting for years. She took a chance on the city, moved in, and began Enventure's Biodesign accelerator. The program shutdown as COVID-19 spread, much like other programs, but Vaught wasn't going to let that stop her momentum.

"A lot of people probably would have seen that as the stopping point but that was actually the beginning of the company," Vaught says on the Houston Innovators Podcast. "What it allowed us to do was actually establish the lab and do the hard work."

As Vaught says, the biotech company, Van Heron Labs, is what it is thanks to the pandemic — not just in spite of it.

"While it's been challenging, the pandemic — in a lot of ways — is the only thing we've ever known and it's a lot of reason why the company has taken off and been successful," Vaught says on the show.

She runs the company with co-founder Alec Santiago and a team of 17 interns — all located across the country. Vaught herself is currently residing in Huntsville, Alabama, after struggling to find lab space in Houston. However, the relocation has been a blessing in disguise.

"Both ecosystems are extremely unique and both bring something different to the table," she says. "My next mission, through my lived experience, is igniting or uniting the Houston and Huntsville biotech ecosystems."

On the episode, Vaught explains how the two cities — each representing key parts of space exploration history and burgeoning tech scene — complement each other. She also shares her plans for growth and the need to bring microbiology into the future.

Listen to the full interview below — or wherever you get your podcasts — and subscribe for weekly episodes.


Pheramor takes users' DNA and social media habits and matches them with compatible partners. Courtesy of Pheramor

Houston DNA-based dating app expands nationwide, launches next funding round

From swiping to swabbing

Houston singles can find their perfect match — even if it's someone across the country. Houston-based Pheramor — a DNA-based dating app — is available for download in every state.

Brittany Barreto, Pheramor's co-founder and CEO, has a PhD in genetics from Baylor College of Medicine. She first had the idea in a genetics seminar when she was 18 and in college, but that was almost 10 years ago, and the market wasn't ready. Now, she says singles have swipe fatigue from the existing and ineffective dating apps, and it's also relatively normal now to send your spit in the mail thanks to 23AndMe.

Pheramor users download the app and request a test kit. After a few cheek swabs, they send it back to Barreto and her team and they identify 11 immune system genes and upload the data to the user's profile. The app then compares the genes to other users to give a compatibility score.

"The science behind attraction based on your DNA is that people are attracted to one another when their immune systems are different — opposites attract is biologically true," Barreto says. "When we were cavewomen and cavemen, we didn't know who was our uncle and who was our cousin, so we used our nose to figure out who is genetically diverse compared to us. If you're genetically diverse, then you're probably not my relative, and therefore we'd have healthier children."

Pheramor also calculates a social score based on a questionnaire or a data mine of a user's social media. The overall compatibility score uses both the DNA and social compatibility scores.

The app launched in Houston in March to a great reception of local singles, but, a few months later, Barreto realized nothing was holding them back from expanding nationwide.

"We surveyed our user base and asked them if they had highly compatible numbers with someone in, say, Chicago, would they want to know," Barreto says. "And something like 89 percent said yes."

Pheramor users are usually between 28 and 38, have good paying jobs, and are seeing commitment, Barreto says. Most of them travel around a lot already.

"We opened it up on September 7, and in 30 days we saw over 50 percent growth in our user base."

The company has zeroed in on a few key metros where advertising dollars go a long way for generating user downloads; Boston, New York, San Francisco, Los Angeles, and Miami have all been great markets for Pheramor.

With the user base growing, Barreto is focused on growing her team. Pheramor's current round of funding launched November 1, and with the capital raised, she hopes to be able to make the team's CFO and chief marketing officer both full time.

Pheramor is also working on using its custom algorithm as a resource to other existing dating services worldwide as well as for couples who want to see their compatibility score with their current partners.

"A long-term goal that's coming to fruition a lot faster than I thought is Pheramor being a leader in genetic testing for romance," Barreto says.

Science of love

Karla Martin/Pheramor

Pheramor CEO and co-founder, Brittany Barreto, first thought of a DNA-based dating company when she was in undergraduate student studying biology. The idea stuck with her as she went through her genetics doctoral program at Baylor College of Medicine.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston hospital names leading cancer scientist as new academic head

new hire

Houston Methodist Academic Institute has named cancer clinician and scientist Dr. Jenny Chang as its new executive vice president, president, CEO, and chief academic officer.

Chang was selected following a national search and will succeed Dr. H. Dirk Sostman, who will retire in February after 20 years of leadership. Chang is the director of the Houston Methodist Dr. Mary and Ron Neal Cancer Center and the Emily Herrmann Presidential Distinguished Chair in Cancer Research. She has been with Houston Methodist for 15 years.

Over the last five years, Chang has served as the institute’s chief clinical science officer and is credited with strengthening cancer clinical trials. Her work has focused on therapy-resistant cancer stem cells and their treatment, particularly relating to breast cancer.

Her work has generated more than $35 million in funding for Houston Methodist from organizations like the National Institutes of Health and the National Cancer Institute, according to the health care system. In 2021, Dr. Mary Neal and her husband Ron Neal, whom the cancer center is now named after, donated $25 million to support her and her team’s research on advanced cancer therapy.

In her new role, Chang will work to expand clinical and translational research and education across Houston Methodist in digital health, robotics and bioengineered therapeutics.

“Dr. Chang’s dedication to Houston Methodist is unparalleled,” Dr. Marc L. Boom, Houston Methodist president and CEO, said in a news release. “She is committed to our mission and to helping our patients, and her clinical expertise, research innovation and health care leadership make her the ideal choice for leading our academic mission into an exciting new chapter.”

Chang is a member of the American Association of Cancer Research (AACR) Stand Up to Cancer Scientific Advisory Council. She earned her medical degree from Cambridge University in England and completed fellowship training in medical oncology at the Royal Marsden Hospital/Institute for Cancer Research. She earned her research doctorate from the University of London.

She is also a professor at Weill Cornell Medical School, which is affiliated with the Houston Methodist Academic Institute.

Texas A&M awarded $1.3M federal grant to develop clean energy tech from electronic waste

seeing green

Texas A&M University in College Station has received a nearly $1.3 million federal grant for development of clean energy technology.

The university will use the $1,280,553 grant from the U.S. Department of Energy to develop a cost-effective, sustainable method for extracting rare earth elements from electronic waste.

Rare earth elements (REEs) are a set of 17 metallic elements.

“REEs are essential components of more than 200 products, especially high-tech consumer products, such as cellular telephones, computer hard drives, electric and hybrid vehicles, and flat-screen monitors and televisions,” according to the Eos news website.

REEs also are found in defense equipment and technology such as electronic displays, guidance systems, lasers, and radar and sonar systems, says Eos.

The grant awarded to Texas A&M was among $17 million in DOE grants given to 14 projects that seek to accelerate innovation in the critical materials sector. The federal Energy Act of 2020 defines a critical material — such as aluminum, cobalt, copper, lithium, magnesium, nickel, and platinum — as a substance that faces a high risk of supply chain disruption and “serves an essential function” in the energy sector.

“DOE is helping reduce the nation’s dependence on foreign supply chains through innovative solutions that will tap domestic sources of the critical materials needed for next-generation technologies,” says U.S. Energy Secretary Jennifer Granholm. “These investments — part of our industrial strategy — will keep America’s growing manufacturing industry competitive while delivering economic benefits to communities nationwide.”

------

This article originally appeared on EnergyCapital.

Biosciences startup becomes Texas' first decacorn after latest funding

A Dallas-based biosciences startup whose backers include millionaire investors from Austin and Dallas has reached decacorn status — a valuation of at least $10 billion — after hauling in a series C funding round of $200 million, the company announced this month. Colossal Biosciences is reportedly the first Texas startup to rise to the decacorn level.

Colossal, which specializes in genetic engineering technology designed to bring back or protect various species, received the $200 million from TWG Global, an investment conglomerate led by billionaire investors Mark Walter and Thomas Tull. Walter is part owner of Major League Baseball’s Los Angeles Dodgers, and Tull is part owner of the NFL’s Pittsburgh Steelers.

Among the projects Colossal is tackling is the resurrection of three extinct animals — the dodo bird, Tasmanian tiger and woolly mammoth — through the use of DNA and genomics.

The latest round of funding values Colossal at $10.2 billion. Since launching in 2021, the startup has raised $435 million in venture capital.

In addition to Walter and Tull, Colossal’s investors include prominent video game developer Richard Garriott of Austin and private equity veteran Victor Vescov of Dallas. The two millionaires are known for their exploits as undersea explorers and tourist astronauts.

Aside from Colossal’s ties to Dallas and Austin, the startup has a Houston connection.

The company teamed up with Baylor College of Medicine researcher Paul Ling to develop a vaccine for elephant endotheliotropic herpesvirus (EEHV), the deadliest disease among young elephants. In partnership with the Houston Zoo, Ling’s lab at the Baylor College of Medicine has set up a research program that focuses on diagnosing and treating EEHV, and on coming up with a vaccine to protect elephants against the disease. Ling and the BCMe are members of the North American EEHV Advisory Group.

Colossal operates research labs Dallas, Boston and Melbourne, Australia.

“Colossal is the leading company working at the intersection of AI, computational biology, and genetic engineering for both de-extinction and species preservation,” Walter, CEO of TWG Globa, said in a news release. “Colossal has assembled a world-class team that has already driven, in a short period of time, significant technology innovations and impact in advancing conservation, which is a core value of TWG Global.”

Well-known genetics researcher George Church, co-founder of Colossal, calls the startup “a revolutionary genetics company making science fiction into science fact.”

“We are creating the technology to build de-extinction science and scale conservation biology,” he added, “particularly for endangered and at-risk species.”